Publication Name	World Journal of Gastroenterology
Manuscript ID	7149
Country	Canada

Received	2013-11-06 09:35
Peer-Review Started	2013-11-06 17:20
To Make the First Decision	2014-01-24 13:14
Return for Revision	2014-01-25 15:17
Revised	2014-02-10 01:30
Second Decision	2014-05-29 20:17
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-29 20:46
Articles in Press	2014-05-29 21:04
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-08-30 15:14
Publish the Manuscript Online	2014-09-18 19:50

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Surgery
Manuscript Type	Retrospective Study
Article Title	McGill Brisbane Symptom Score for patients with resectable pancreatic head adenocarcinoma
Manuscript Source	Invited Manuscript
All Author List	Mohammed H Jamal, Suhail A R Doi, A James Moser, Sinziana Dumitra, Jad abou Khalil, Eve Simoneau, Prosanto Chaudhury, Adedayo A Onitilo, Peter Metrakos and Jeffrey S Barkun
Funding Agency and Grant Number
Corresponding Author	Jeffrey S Barkun, MD, Division of General Surgery, Department of Surgery, Royal Victoria Hospital, S9.30 RVH, 687 Pine Ave, W, Montréal, Québec H3A 1A1, Canada. jeffrey.barkun@muhc.mcgill.ca
Key Words	Pancreatic neoplasms; Pancreatic adenocarcinoma; Whipple procedure; Prognosis; Survival study; Chemotherapy
Core Tip	The McGill Brisbane Symptom Score (MBSS) was described and validated as a score to predict survival in patients with unresectable pancreatic adenocarcinoma. In this paper we validate it in a cohort of patients with resectable pancreatic head adenocarcinoma. It is a simple yet powerful preoperative tool that can potentially guide therapy and stratify patients for neoadjuvant or adjuvant chemotherapy trials. We also found in this study that adjuvant chemotherapy seems to be effective only in patients in the high MBSS group but adds no additional survival benefit in patients in the low MBSS group. The MBSS seems to provide a better discrimination in survival than any conventional preoperative method.
Publish Date	2014-09-18 19:50
Citation	Jamal MH, Doi SAR, Moser AJ, Dumitra S, abou Khalil J, Simoneau E, Chaudhury P, Onitilo AA, Metrakos P, Barkun JS. McGill Brisbane Symptom Score for patients with resectable pancreatic head adenocarcinoma. World J Gastroenterol 2014; 20(34): 12226-12232
URL	http://www.wjgnet.com/1007-9327/full/v20/i34/12226.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i34.12226

Full Article (PDF)	WJG-20-12226.pdf
Full Article (Word)	WJG-20-12226.doc
Manuscript File	7149-Review.docx
Answering Reviewers	7149-Answering reviewers.pdf
Copyright License Agreement	7149-Copyright assignment.pdf
Peer-review Report	7149-Peer reivew(s).pdf
Scientific Misconduct Check	7149-CrossCheck.jpg
Scientific Editor Work List	7149-Scientific editor work list.pdf